Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Research & Development of $430895.0 for Q1 2026, down 95.9% year-over-year from $10.5 million in Q1 2025, and down 93.22% quarter-over-quarter from $6.4 million in Q4 2025.
Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Research & Development for 7 consecutive years, with $430895.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 95.9% year-over-year to $430895.0; the TTM figure through Mar 2026 stood at $12.1 million (down 51.48% YoY), while the FY2025 annual figure was $29.8 million, up 73.11% from the prior year.
- Research & Development retreated to $430895.0 in Q1 2026 per IKT's latest filing, from $6.4 million in the prior quarter.
- Across five years, Research & Development topped out at $13.6 million in Q4 2023 and bottomed at $55114.0 in Q3 2025.
- Historically, Research & Development has averaged $4.5 million across 5 years, with a median of $3.1 million in 2024.
- Annual changes were most pronounced in 2023 — Research & Development jumped 344.91% — and 2025, when it slumped 98.68%.
- Inhibikase Therapeutics' Research & Development stood at $3.1 million in 2022, then jumped by 344.91% to $13.6 million in 2023, then slumped by 47.06% to $7.2 million in 2024, then fell by 11.6% to $6.4 million in 2025, then sank by 93.22% to $430895.0 in 2026.
- Business Quant data shows IKT's Research & Development at $430895.0 in Q1 2026, $6.4 million in Q4 2025, and $55114.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 13.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.39 Mn |
| Mar 31, 2026 | 430,895.00 |
| Dec 31, 2025 | 6.36 Mn |
| Sep 30, 2025 | 55,114.00 |
| Jun 30, 2025 | 5.27 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 7.19 Mn |
| Sep 30, 2024 | 4.19 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Dec 31, 2023 | 13.59 Mn |
| Sep 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Mar 31, 2023 | 2.85 Mn |
| Dec 31, 2022 | 3.05 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 2.98 Mn |
| Mar 31, 2022 | 3.02 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 3.15 Mn |